CVS Health on Wednesday outpaced Wall Street’s expectations for first-quarter earnings and raised its guidance for the year, as it saw demand for at-home Covid tests, prescriptions and more.
Shares were up more than 1% in premarket trading.
Here’s how the company reported for the three-month period ended March 31, compared with what analysts were expecting, based on a survey of analysts by Refinitiv:
- Earnings per share: $2.22 adjusted vs. $2.15 expected
- Revenue: $76.83 billion vs. $75.39 billion expected
The health-care company reported net income of $2.31 billion, or $1.74 per share, higher than the $2.22 billion, or $1.68 per share, a year earlier.
Excluding items, CVS earned $2.22 per share, more thanthe $2.15 per share expected by analysts surveyed by Refinitiv.
Revenue increased to $76.83 billion from$69.1 billion a year earlier. That topped/fell short of analysts’ expectations of $75.39 billion.
As of Tuesday’s close, shares of CVS are down about 7% so far this year, outperforming the 12% decline of the S&P 500. Shares closed Tuesday at $95.98, bringing the company’s market value to $126.04 billion.
This story is developing. Please check back for updates.